Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects With Diabetic Macular Edema

  • days left to enroll
  • participants needed
  • sponsor
    Michelle Abou-Jaoude
Updated on 12 April 2023


This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).

Condition Diabetic Macular Edema
Treatment K8
Clinical Study IdentifierNCT05699759
SponsorMichelle Abou-Jaoude
Last Modified on12 April 2023


Yes No Not Sure

Inclusion Criteria

years or older
BCVA of ≥ 24 and ≤ 73 letters (20/40 or worse but at least 20/320) by an ETDRS chart. BCVA of the non-study eye must be no worse than 20/400)
Diagnosis of diabetes mellitus, type 1 or 2 with non-proliferative or non-high risk proliferative diabetic retinopathy
DME based on investigator's clinical evaluation and demonstrated on fundus photographs, fluorescein angiograms, and spectral domain-optical coherence tomography (SD-OCT)
Mean foveal thickness of at least 300 µm by SD-OCT
Ability and willingness to comply with the treatment and follow-up procedures
Ability to understand and sign the informed consent form
Intraocular pressure of ≤ 21 on 2 or less IOP lowering medications

Exclusion Criteria

Pregnant patients, currently lactating patients, or females of childbearing potential (unless using reliable contraception such as double barrier, surgical sterilization, oral contraceptives, intrauterine device (IUD), etc.)
Allergy or hypersensitivity (known or suspected) to fluorescein or any component of the investigational product or delivery system
Any ocular surgery in the study eye within 12 weeks of screening
Any history of vitrectomy in the study eye
Aphakia in the study eye
Presence of severe foveal ischemia, defined as foveal avascular zone (FAZ) of >1.5 mm2 on OCT-Angiography
Prior intraocular or periocular treatment for DME
Macular laser for the treatment of diabetic macular edema within 12 weeks of screening
Any change in systemic steroidal therapy within 3 months of screening
Retinal or choroidal neovascularization due to ocular conditions other than diabetic retinopathy
History or presence of viral disease of the cornea or conjunctiva
History or presence of any disease or condition that in the investigator's opinion would preclude study treatment or follow-up or that in the opinion of the investigator would render them as unlikely to benefit from study treatment
Any lens or corneal opacity which impairs visualization of the posterior pole
Participation in another clinical trial within 12 weeks before the screening visit or during the study
Expectation that subject will be moving away from the area of the clinical treatment center without the ability to return for visits within the study period
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note